Medtronic Receives FDA Clearance, CE Mark For Its Affera Prism-2 Mapping Software, Also Receives CE Mark For PulseSelect ProxBox Adapter
Medtronic (NYSE: MDT), a global leader in healthcare technology, today announced regulatory milestones for software used with two cardiac ablation platforms. This includes U.S. Food and Drug Administration (FDA)
Medtronic got official approval for new heart surgery mapping software. This means the company can sell these tools in the U.S. and Europe now.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.